Filtered By:
Condition: Thrombocytopenia
Cancer: Lymphoma
This page shows you your search results in order of date.
Order by Relevance | Date
Total 291 results found since Jan 2013.
Nine-year Follow-up of Lenalidomide Plus Rituximab as Initial Treatment for Mantle Cell Lymphoma
We report 9-year follow up of a multi-center phase 2 study of lenalidomide plus rituximab (LR) as initial treatment of MCL. The LR doublet is used as induction and maintenance until progression, with optional discontinuation after 3 years. We previously reported an overall response rate in evaluable patients of 92%, with 64% achieving a complete response. At a median follow up of 103 months, 17 (47%) of 36 evaluable patients remain in remission. The 9-year progression-free survival (PFS) and overall survival (OS) were 51% and 66%, respectively. During maintenance, hematologic adverse events (AEs) included asymptomatic grad...
Source: Adv Data - September 8, 2023 Category: Epidemiology Authors: Samuel Yamshon Gui Chen Caitlin Gribbin Paul Christos Bijal D Shah Stephen J Schuster Sonali M Smith Jakub Svoboda Richard R Furman John P Leonard Peter Martin Jia Ruan Source Type: research
Phase 1 Dose Escalation and Expansion Study of Golidocitinib, a Highly Selective JAK1 Inhibitor, in Relapsed or Refractory Peripheral T Cell Lymphomas
CONCLUSIONS: In this phase 1 study, golidocitinib demonstrated an acceptable safety profile and encouraging antitumor efficacy in heavily pre-treated patients with r/r PTCLs. These results support the initiation of the multinational pivotal study in patients with r/r PTCLs.PMID:37673210 | DOI:10.1016/j.annonc.2023.08.013
Source: Ann Oncol - September 6, 2023 Category: Cancer & Oncology Authors: Y Song D H Yoon H Yang J Cao D Ji Y Koh H Jing H Eom J Kwak W Lee J Lee H Shin J Jin M Wang Z Yang W Kim J Zhu Source Type: research
Real World Efficacy and Toxicity of Selinexor: Importance of Patient Characteristics, Dose Intensity and Post Progression Outcomes
CONCLUSION: In conclusion, selinexor-based therapy provides an additional treatment option in the real word setting and with appropriate dosing and toxicity management a subset of patients may have significant benefit.PMID:37599164 | DOI:10.1016/j.clml.2023.07.013
Source: Clinical Lymphoma and Myeloma - August 20, 2023 Category: Cancer & Oncology Authors: Efstathios Kastritis Maria Gavriatopoulou Eirini Solia Foteini Theodorakakou Vasiliki Spiliopoulou Panagiotis Malandrakis Ioannis Ntanasis-Stathopoulos Magdalini Migkou Nikoleta Kokkali Evangelos Eleutherakis-Papaiakovou Rodanthi Syrigou Despina Fotiou Ev Source Type: research
Predictive model for treatment outcomes of peripheral T-cell lymphoma, not otherwise specified, in Taiwanese patients
CONCLUSION: PTCL-NOS patients have a dismal prognosis in Taiwan. Novel agents may improve the outcomes of PTCL-NOS patients. The usefulness of the novel prognostic index for PTCL-NOS needs further validation.PMID:37558588 | DOI:10.1016/j.jfma.2023.07.014
Source: J Formos Med Assoc - August 9, 2023 Category: General Medicine Authors: Ning-Chun Chen Hung Chang Ming-Chung Kuo Tung-Liang Lin Lee-Yung Shih Wen-Yu Chuang Hsiao-Wen Kao Source Type: research
ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma
CONCLUSION: The combination of ZO met its primary endpoint of a superior ORR versus O, and demonstrated meaningful activity and a manageable safety profile in patients with R/R FL. ZO had a favorable benefit-risk profile compared with O, and represents a potential combination therapy for patients with R/R FL.PMID:37506346 | DOI:10.1200/JCO.23.00775
Source: Clinical Lymphoma and Myeloma - July 28, 2023 Category: Cancer & Oncology Authors: Pier Luigi Zinzani Ji ří Mayer Christopher R Flowers Fontanet Bijou Ana C De Oliveira Yuqin Song Qingyuan Zhang Michele Merli Krimo Bouabdallah Peter Ganly Huilai Zhang Roderick Johnson Alejandro Mart ín García-Sancho Mariano Provencio Pulla Marek Trn Source Type: research
Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors
CONCLUSIONS: JNJ-64619178 demonstrated manageable dose-dependent toxicity and preliminary evidence of antitumor activity in ACC and other tumor types. Plasma exposure was dose dependent, and target inhibition was maintained with intermittent and continuous dosing. Based on safety, clinical activity, PK, and PD findings, two provisional RP2Ds were selected: 1.5 mg intermittently and 1.0 mg once daily. Aside from ACC, clinical benefit was limited, and biomarkers to enrich for responsiveness to PRMT5 inhibition will be needed for further development.PMID:37491846 | DOI:10.1158/1078-0432.CCR-23-0092
Source: Clinical Cancer Research - July 26, 2023 Category: Cancer & Oncology Authors: Maria Vieito Victor Moreno Anna Spreafico Irene Brana Judy S Wang Meir Preis Tatiana Hernandez-Guerrero Sofia Genta Aaron R Hansen Bernard Doger Vladimir Galvao Laurie Lenox Regina J Brown Anna Kalota Jaydeep Mehta Friederike Pastore Bharvin Patel Pankaj Source Type: research
Safety and efficacy of tenalisib in combination with romidepsin in patients with relapsed/refractory T-cell lymphoma: results from a phase I/II open-label multicenter study
Haematologica. 2023 Jul 13. doi: 10.3324/haematol.2022.281875. Online ahead of print.ABSTRACTTenalisib, a selective phosphoinositide-3-kinase δ/γ, and salt-inducible-kinase-3 inhibitor has shown efficacy and was well-tolerated in patients with T-cell lymphoma (TCL). In vitro studies suggest a synergistic anti-tumor potential for the combination of tenalisib with the histone-deacetylase inhibitor, romidepsin. This multicenter, open-label, phase I/II study was designed to characterize the safety, efficacy and pharmacokinetics of oral tenalisib twicedaily (BID) and intravenous (IV) romidepsin administered on Days 1, 8 and 1...
Source: Haematologica - July 13, 2023 Category: Hematology Authors: Swaminathan P Iyer Auris Huen Weiyun Z Ai Deepa Jagadeesh Mary J Lechowicz Craig Okada Tatyana A Feldman Paola Ghione Juan P Alderuccio Rebecca Champion Seo-Hyun Kim Ann Mohrbacher Kasi V Routhu Prajak Barde Ajit M Nair Bradley M Haverkos Source Type: research
